Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 14/20 | 0.69 |
| ▸ | INSR | P06213 | 11/20 | 0.69 |
| ▸ | IGF1R | P08069 | 11/20 | 0.69 |
| ▸ | EGFR | P00533 | 8/20 | 0.62 |
| ▸ | MET | P08581 | 3/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.58 |
| ▸ | AURKA | O14965 | 2/20 | 0.58 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.58 |
| ▸ | JAK2 | O60674 | 2/20 | 0.58 |
| ▸ | STK10 | O94804 | 2/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 2/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.58 |
| ▸ | FYN | P06241 | 2/20 | 0.58 |
| ▸ | FES | P07332 | 2/20 | 0.58 |
| ▸ | CSF1R | P07333 | 2/20 | 0.58 |
| ▸ | YES1 | P07947 | 2/20 | 0.58 |
| ▸ | LYN | P07948 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26778379 | 0.92 | ALK (0.61) | ALKINSRIGF1REGFRMET | |
| SCHEMBL24326981 | 0.92 | EGFR (0.62) | ALKINSRIGF1REGFRMET | |
| SCHEMBL26778364 | 0.90 | ALK (0.77) | ALKINSRIGF1REGFRMET | |
| SCHEMBL24327657 | 0.90 | ALK (0.66) | ALKINSRIGF1REGFRMET | |
| SCHEMBL30223482 | 0.89 | ALK (0.62) | ALKINSRIGF1REGFRMET | |
| SCHEMBL24327532 | 0.87 | ALK (0.52) | ALKINSRIGF1REGFRMET | |
| SCHEMBL29661502 | 0.87 | ALK (0.52) | ALKINSRIGF1REGFRMET | |
| SCHEMBL24327366 | 0.87 | EGFR (0.55) | ALKINSRIGF1REGFRZAP70 | |
| SCHEMBL29661303 | 0.86 | ALK (0.75) | ALKINSRIGF1REGFRMET | |
| SCHEMBL26778353 | 0.86 | ALK (0.75) | ALKINSRIGF1REGFRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | ALK 13/4885INSR 82/4885IGF1R 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.